SPSB1 promotes breast cancer recurrence by potentiating c-MET signaling
Cancer Discovery, ISSN: 2159-8290, Vol: 4, Issue: 7, Page: 790-803
2014
- 36Citations
- 38Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations36
- Citation Indexes36
- 36
- CrossRef31
- Captures38
- Readers38
- 38
Article Description
Breast cancer mortality is principally due to tumor recurrence; however, the molecular mechanisms underlying this process are poorly understood. We now demonstrate that the suppressor of cytokine signaling protein SPSB1 is spontaneously upregulated during mammary tumor recurrence and is both necessary and sufficient to promote tumor recurrence in genetically engineered mouse models. The recurrence-promoting effects of SPSB1 result from its ability to protect cells from apoptosis induced by HER2/neu pathway inhibition or chemotherapy. This, in turn, is attributable to SPSB1 potentiation of c-MET signaling, such that preexisting SPSB1-overexpressing tumor cells are selected for following HER2/neu downregulation. Consistent with this, SPSB1 expression is positively correlated with c-MET activity in human breast cancers and with an increased risk of relapse in patients with breast cancer in a manner that is dependent upon c-MET activity. Our findings define a novel pathway that contributes to breast cancer recurrence and provide the first evidence implicating SPSB proteins in cancer. © 2014 American Association for Cancer Research.
Bibliographic Details
http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=84904037075&origin=inward; http://dx.doi.org/10.1158/2159-8290.cd-13-0548; http://www.ncbi.nlm.nih.gov/pubmed/24786206; https://aacrjournals.org/cancerdiscovery/article/4/7/790/4409/SPSB1-Promotes-Breast-Cancer-Recurrence-by; http://cancerdiscovery.aacrjournals.org/cgi/doi/10.1158/2159-8290.CD-13-0548; https://syndication.highwire.org/content/doi/10.1158/2159-8290.CD-13-0548; https://dx.doi.org/10.1158/2159-8290.cd-13-0548; https://cancerdiscovery.aacrjournals.org/content/4/7/790; https://cancerdiscovery.aacrjournals.org/content/4/7/790.abstract; https://cancerdiscovery.aacrjournals.org/content/candisc/4/7/790.full.pdf; http://cancerdiscovery.aacrjournals.org/lookup/doi/10.1158/2159-8290.CD-13-0548; http://cancerdiscovery.aacrjournals.org/content/4/7/790
American Association for Cancer Research (AACR)
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know